CUE Kenneth Pienta buys $15K worth of shares
Jan 08, 2026, 11:36 AM
-2.47%
What does CUE do
Cue Biopharma, a Boston-based clinical-stage biopharmaceutical company, develops biologic drugs for immune system modulation to treat cancers and autoimmune disorders. Its key candidates include CUE-101 for HPV-positive HNSCC and CUE-102 for Wilms' Tumor 1 protein.
Kenneth Pienta bought 2,000 shares of CUE on 27 December at $7.50 per share, worth a total of $15K. They now own 2,000 CUE shares.
📡️ Health Care
Insider Trades
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.